Neurocrine Announces Ingrezza (valbenazine) NDA for the Treatment of Tardive Dyskinesia has been Accepted for Priority Review by FDA

SAN DIEGO, Oct. 11, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for Ingrezza (valbenazine) for the...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news